MX368767B - (5,6-dihidro)pirimido[4,5-e]indolizinas. - Google Patents

(5,6-dihidro)pirimido[4,5-e]indolizinas.

Info

Publication number
MX368767B
MX368767B MX2016012997A MX2016012997A MX368767B MX 368767 B MX368767 B MX 368767B MX 2016012997 A MX2016012997 A MX 2016012997A MX 2016012997 A MX2016012997 A MX 2016012997A MX 368767 B MX368767 B MX 368767B
Authority
MX
Mexico
Prior art keywords
indolizines
pyrimido
dihydro
cancer
aryl
Prior art date
Application number
MX2016012997A
Other languages
English (en)
Other versions
MX2016012997A (es
Inventor
Petrus Antonius De Man Adrianus
Christian Buijsman Rogier
Gerard STERRENBURG Jan
Cornelis Marinus UITDEHAAG Joost
Johannes Petrus DE WIT Joeri
Jenny Rudolf Zaman Guido
Original Assignee
Netherlands Translational Res Center B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Netherlands Translational Res Center B V filed Critical Netherlands Translational Res Center B V
Publication of MX2016012997A publication Critical patent/MX2016012997A/es
Publication of MX368767B publication Critical patent/MX368767B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a un compuesto de fórmula I: (ver Fórmula) Fórmula I, en donde, R1 y R2 se seleccionan independientemente entre el grupo que consiste de arilo de (C6-10) opcionalmente sustituido y grupos heteroarilo de (C1-5); los compuestos se pueden utilizar en composiciones farmacéuticas, en particular en el tratamiento del cáncer.
MX2016012997A 2014-04-07 2015-03-30 (5,6-dihidro)pirimido[4,5-e]indolizinas. MX368767B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14163734 2014-04-07
EP15153207 2015-01-30
PCT/EP2015/056839 WO2015155042A1 (en) 2014-04-07 2015-03-30 (5,6-dihydro)pyrimido[4,5-e]indolizines

Publications (2)

Publication Number Publication Date
MX2016012997A MX2016012997A (es) 2016-12-07
MX368767B true MX368767B (es) 2019-10-15

Family

ID=52774240

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016012997A MX368767B (es) 2014-04-07 2015-03-30 (5,6-dihidro)pirimido[4,5-e]indolizinas.

Country Status (16)

Country Link
US (3) USRE48974E1 (es)
EP (1) EP3129374B1 (es)
JP (1) JP6518690B2 (es)
KR (1) KR102432420B1 (es)
CN (1) CN106132963B (es)
AU (1) AU2015243694B2 (es)
BR (1) BR112016022342B1 (es)
CA (1) CA2944610C (es)
DK (1) DK3129374T3 (es)
ES (1) ES2716165T3 (es)
HU (1) HUE043108T2 (es)
MX (1) MX368767B (es)
PL (1) PL3129374T3 (es)
PT (1) PT3129374T (es)
RU (1) RU2692479C2 (es)
WO (1) WO2015155042A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2944610C (en) * 2014-04-07 2024-01-09 Netherlands Translational Research Center B.V. (5,6-dihydro)pyrimido[4,5-e]indolizines
ES2966392T3 (es) * 2015-04-17 2024-04-22 Crossfire Oncology Holding B V Biomarcadores pronósticos para quimioterapia inhibidora de TTK
DK3416964T3 (da) * 2016-02-19 2021-02-22 Phoenix Molecular Designs 6-Oxo-N-(1-(benzyl)-1H-pyrazol-4-YL)-6,7,8,9-tetrahydropyrido[3',2':4,5]pyrrolo[1,2-A]pyrazin-2-carboxamid-derivater som P90 ribosomal S6 kinase- (RSK-) hæmmere til behandling af cancer
KR20210141778A (ko) 2016-06-07 2021-11-23 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
CN106551938B (zh) * 2016-11-26 2017-11-24 广东安诺药业股份有限公司 一种治疗非酒精性脂肪肝的药物及其应用
KR20220113545A (ko) 2017-03-23 2022-08-12 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
WO2023113478A1 (en) * 2021-12-15 2023-06-22 Sillajen, Inc. Methods of treating neoplastic diseases
EP4447970A1 (en) * 2021-12-15 2024-10-23 SillaJen, Inc. Pharmaceutical combinations for use in the treatment of neoplastic diseases
WO2023113479A1 (en) * 2021-12-15 2023-06-22 Sillajen, Inc. Pharmaceutical compositions comprising modified beta-cyclodextrins
WO2023167549A1 (en) * 2022-03-04 2023-09-07 Sillajen, Inc. Pharmaceutical combinations for use in the treatment of neoplastic diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100391958C (zh) * 2001-09-19 2008-06-04 安万特医药股份有限公司 化合物
CN1826343A (zh) 2003-05-22 2006-08-30 法玛西雅意大利公司 吡唑并-喹唑啉衍生物、它们的制备方法和它们作为激酶抑制剂的用途
US8207180B2 (en) 2006-11-28 2012-06-26 Nerviano Medical Sciences S.R.L. Tricyclic indoles and (4,5-dihydro) indoles
CN102076689B (zh) * 2008-06-26 2014-10-15 内尔维阿诺医学科学有限公司 吡唑并-喹唑啉类
WO2010111406A2 (en) 2009-03-24 2010-09-30 Myriad Pharmaceuticals, Inc. Compounds and therapeutic uses thereof
JP5801285B2 (ja) 2009-04-29 2015-10-28 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ Cdk阻害物質の塩
CN103626777B (zh) 2009-07-29 2015-10-21 内尔维阿诺医学科学有限公司 Plk抑制剂的盐类
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
US20130303532A1 (en) 2010-12-17 2013-11-14 Bayer Intellectual Property Gmbh Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders
CN103339134B (zh) * 2011-01-26 2015-12-23 内尔维阿诺医学科学有限公司 三环吡咯并衍生物、它们的制备方法和它们作为激酶抑制剂的应用
JP6523267B2 (ja) 2013-06-24 2019-05-29 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Fshrの調節剤としてのイミダゾール化合物及びその使用
CA2944610C (en) * 2014-04-07 2024-01-09 Netherlands Translational Research Center B.V. (5,6-dihydro)pyrimido[4,5-e]indolizines

Also Published As

Publication number Publication date
RU2692479C2 (ru) 2019-06-25
USRE48974E1 (en) 2022-03-15
KR102432420B1 (ko) 2022-08-17
USRE50082E1 (en) 2024-08-20
RU2016141405A (ru) 2018-05-07
JP6518690B2 (ja) 2019-05-22
EP3129374B1 (en) 2018-12-19
ES2716165T3 (es) 2019-06-10
PT3129374T (pt) 2019-03-25
AU2015243694A1 (en) 2016-11-03
BR112016022342B1 (pt) 2022-10-04
RU2016141405A3 (es) 2018-10-02
CA2944610C (en) 2024-01-09
BR112016022342A8 (pt) 2021-07-20
MX2016012997A (es) 2016-12-07
DK3129374T3 (en) 2019-04-08
US20170096432A1 (en) 2017-04-06
WO2015155042A1 (en) 2015-10-15
JP2017510595A (ja) 2017-04-13
AU2015243694B2 (en) 2019-01-17
BR112016022342A2 (pt) 2017-08-15
US9856258B2 (en) 2018-01-02
CN106132963B (zh) 2019-08-06
CA2944610A1 (en) 2015-10-15
KR20170013866A (ko) 2017-02-07
HUE043108T2 (hu) 2019-07-29
EP3129374A1 (en) 2017-02-15
PL3129374T3 (pl) 2019-07-31
CN106132963A (zh) 2016-11-16

Similar Documents

Publication Publication Date Title
MX2016012997A (es) (5,6-dihidro)pirimido[4,5-e]indolizinas.
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
CA2999253C (en) Heterocyclic compounds and uses thereof
EA033266B1 (ru) Гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их
CL2016002735A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
PH12018500987A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
TN2017000524A1 (en) New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
MY190243A (en) Hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
GEP20186887B (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
JO3195B1 (ar) مشتقات أندوليزين جديدة, وطريقة تحضيرهم والتركيبات الصيدلانية التي تحتوي عليهم لعلاج السرطان
EP3597649B8 (en) Compositions containing substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as pde2 inhibitors
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
MD4820B1 (ro) Compuşi dihidroizochinolinonici substituiţi
MX362215B (es) Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1.
MY191628A (en) Novel triazolo[4,5-d]pyrimidine derivatives
TN2015000262A1 (en) Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors
JO3310B1 (ar) مشتقات إندوليزين جديدة وطريقة لإنتاجها وتركيبات صيدلانية تحتوي عليها
AU2015352440B2 (en) Compounds
TW201613864A (en) Novel compounds
HK1247203A1 (zh) 取代的咪唑並[1,2-α]吡啶-2-基胺化合物及其藥物組合物和使用方法
CY1120602T1 (el) [1,2,4]τριαζολο[4,3-β]πυριδαζινες για χρηση στη θεραπευτικη αντιμετωπιση πολλαπλασιαστικων ασθενειων
TN2018000090A1 (en) New imidazo[4,5-b]pyridine derivatives as dual dyrk1/clk1 inhibitors
PH12017500342A1 (en) 7 - (morpholinyl) -2- (n-piperazinyl) methyl thieno [2,3-c] pyridine derivatives as anticancer drugs
PH12016501997A1 (en) Cycloalkyl-linked diheterocycle derivatives
MX2017006051A (es) Derivados de 2,3-dihidro-tiazolo[3,2-a]piridin-5-ona, intermediarios de los mismos, y su uso como agentes antibacterianos.

Legal Events

Date Code Title Description
FG Grant or registration